Successful Completion of First Group in Phase I Human Trial
Filed with ASX · · 2 pages · English
Vectus Biosystems Limited (Vectus or the Company) is pleased to announce that the first cohort consisting of eight subjects has completed all protocol requirements for the 2mg dose in the Single Ascending Dose (SAD) component of its Phase I/IB trial entitled: “A phase I/Ib, first-time-in-human, single centre, double blind, randomised, placebo-controlled, dose-escalating study of the safety, tolera
Vectus Biosystems Limited on 6ix
Earlier from Vectus Biosystems
- Approval Received for Phase I Trial in Australia
- Vectus completes $7 million placement
- Proposed issue of Securities - VBS
- Quarterly Activities Report and Appendix 4C
- Appendix 4C - Quarterly Report
Later from Vectus Biosystems
- Update on Phase I Human Trial
- Response to ASX Price and Volume Query
- Third S.A.D. Group Reviewed By Trial Safety Review Committee
- Chairman & CEO Address to Shareholders
- A Significant Milestone for VB0004
Follow Vectus Biosystems into a list and get an email when it puts out news.
Follow Vectus Biosystems